Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? (Q47877385)

6 February 2018

title

Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? (English)

1 reference

6 February 2018

main subject

Guillain–Barré syndrome

0 references

1 reference

1

Koga M

1 reference

6 February 2018

Nobuhiro Yuki

2

object named as

Yuki N

1 reference

6 February 2018

author name string

Ariga T

3

1 reference

6 February 2018

Morimatsu M

4

1 reference

6 February 2018

Hirata K

5

1 reference

6 February 2018

publication date

1 June 1998

1 reference

6 February 2018

Journal of Neuroimmunology

published in

1 reference

6 February 2018

volume

86

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

74-79

1 reference

6 February 2018

Assessment of current diagnostic criteria for Guillain-Barré syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Anti-GD1a ganglioside antibodies in peripheral motor syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Improved method for large-scale purification of brain gangliosides by Q-sepharose column chromatography. Immunochemical detection of C-series polysialogangliosides in adult bovine brains

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Evidence for direct binding of Clostridium botulinum type E derivative toxin and its fragments to gangliosides and free fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Interaction between Clostridium botulinum neurotoxin and gangliosides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Acute motor axonal neuropathy with high titer IgG and IgA anti-GD1 a antibodies following Campylobacter enteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Unusual clinical variants and signs in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900016-2

7 January 2021

10.1016/S0165-5728(98)00016-2

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

9655474

1 reference

6 February 2018